Medicenna Therapeutics Corp.
MDNAF
$0.744
-$0.016-2.11%
| Weiss Ratings | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.86 | |||
| Price History | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.98% | |||
| 30-Day Total Return | -14.29% | |||
| 60-Day Total Return | -39.51% | |||
| 90-Day Total Return | -56.24% | |||
| Year to Date Total Return | -33.27% | |||
| 1-Year Total Return | -35.14% | |||
| 2-Year Total Return | 32.86% | |||
| 3-Year Total Return | -45.69% | |||
| 5-Year Total Return | -54.36% | |||
| 52-Week High % Change | -66.18% | |||
| 52-Week Low % Change | 22.37% | |||
| Price | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.20 | |||
| 52-Week Low Price | $0.61 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Jun 03, 2024 | |||
| Valuation | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 58.03M | |||
| Enterprise Value | 37.16M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.27 | |||
| Earnings Per Share Growth | 65.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 4.80 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.74 | |||
| Enterprise Value/EBITDA (TTM) | -2.73 | |||
| Enterprise Value/EBIT | -2.73 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 78.01M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416 648 5555 | |||
| Address | 2 Bloor Street West Toronto, ON M4W 3E2 | |||
| Website | www.medicenna.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -42.57% | |||
| Return on Equity | -- | |||
| Income Statement | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -13.62M | |||
| EBIT (TTM) | -13.63M | |||
| Net Income (TTM) | -19.73M | |||
| Net Income Avl. to Common (TTM) | -19.73M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -1.37% | |||
| EPS Diluted (TTM) | -0.27 | |||
| EPS Diluted Growth (Q YOY) | 9.52% | |||
| Balance Sheet | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 20.85M | |||
| Cash Per Share (Q) | $0.27 | |||
| Total Current Assets (Q) | 22.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 12.13M | |||
| Current Ratio (Q) | 10.086 | |||
| Book Value Per Share (Q) | $0.16 | |||
| Total Assets (Q) | 22.41M | |||
| Total Current Liabilities (Q) | 2.21M | |||
| Total Debt (Q) | 120.90K | |||
| Total Liabilities (Q) | 10.28M | |||
| Total Common Equity (Q) | 12.13M | |||
| Cash Flow | MDNAF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -24.20K | |||
| Cash from Financing (TTM) | 17.15M | |||
| Net Change in Cash (TTM) | 5.96M | |||
| Levered Free Cash Flow (TTM) | -8.36M | |||
| Cash from Operations (TTM) | -11.95M | |||
